ArticleAsian Pacific journal of cancer prevention : APJCP2025
Bioinformatics Analysis of Programmed Death-1-Trastuzumab Resistance Regulatory Networks in Breast Cancer Cells.
Article in Asian Pacific journal of cancer prevention : APJCP, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Tumor-Intrinsic PD-1 Regulatory Network Drives Lapatinib Resistance in HER2⁺ Breast Cancer: An Integrative Bioinformatics Analysis.Asian Pacific journal of cancer prevention : APJCP · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectiveProgrammed cell death-1 (PD-1, encoded by PDCD1) regulatory network participates in glioblastoma multiforme development. However, such a network in trastuzumab-resistant human epidermal growth factor receptor 2-positive (HER2+) breast cancer remains to be determined. Accordingly, this study was aimed to explore the PD-1 regulatory network responsible for the resistance of breast cancer cells to trastuzumab through a bioinformatics approach.
methodsThe study used data mining tools like cBioportal and OMIM to identify genes involved in the programmed cell death-1-trastuzumab resistance regulatory network. The network was further examined using various tools like WebGestalt, DAVID, STRING, Cytoscape, CytoHubba, GEPIA, TNMPlot, and ROCPlot.
resultsThe PDCD1 regulatory network in trastuzumab-resistant HER2+ breast cancer is linked to Cytotoxic T-lymphocyte-associated antigen 4 (CTLA-4), interleukin (IL)-10, protein tyrosine phosphatase receptor type C (PTPRC), and FCGR2B. These factors have a significant prognostic power in pathological complete response in breast cancer patients treated with trastuzumab. Infiltration of B cells, CD8+ cells, CD4+ cells, neutrophils, dendritic cells, macrophages, and regulatory T cells is directly correlated with PTR expression.
conclusionThe study identified four genes (CTLA4, IL10, PTPRC, and FCGR2B) that are linked to the regulatory network of PD-1 in trastuzumab-resistant HER2+ breast cancer cells. Further research is needed to develop the therapeutic target against trastuzumab resistance in HER2+ breast cancer.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.